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Articles
Chromatin organisation and cancer prognosis: a pan-cancer 
study
Andreas Kleppe, Fritz Albregtsen, Ljiljana Vlatkovic, Manohar Pradhan, Birgitte Nielsen, Tarjei S Hveem, Hanne A Askautrud, Gunnar B Kristensen, 
Arild Nesbakken, Jone Trovik, Håkon Wæhre, Ian Tomlinson, Neil A Shepherd, Marco Novelli, David J Kerr, Håvard E Danielsen
Summary
Background Chromatin organisation affects gene expression and regional mutation frequencies and contributes to 
carcinogenesis. Aberrant organisation of DNA has been correlated with cancer prognosis in analyses of the chromatin 
component of tumour cell nuclei using image texture analysis. As yet, the methodology has not been sufficiently 
validated to permit its clinical application. We aimed to define and validate a novel prognostic biomarker for the 
automatic detection of heterogeneous chromatin organisation.
Methods Machine learning algorithms analysed the chromatin organisation in 461 000 images of tumour cell nuclei 
stained for DNA from 390 patients (discovery cohort) treated for stage I or II colorectal cancer at the Aker University 
Hospital (Oslo, Norway). The resulting marker of chromatin heterogeneity, termed Nucleotyping, was subsequently 
independently validated in six patient cohorts: 442 patients with stage I or II colorectal cancer in the Gloucester 
Colorectal Cancer Study (UK); 391 patients with stage II colorectal cancer in the QUASAR 2 trial; 246 patients with 
stage I ovarian carcinoma; 354 patients with uterine sarcoma; 307 patients with prostate carcinoma; and 791 patients 
with endometrial carcinoma. The primary outcome was cancer-specific survival.
Findings In all patient cohorts, patients with chromatin heterogeneous tumours had worse cancer-specific survival 
than patients with chromatin homogeneous tumours (univariable analysis hazard ratio [HR] 1·7, 95% CI 1·2–2·5, 
in the discovery cohort; 1·8, 1·0–3·0, in the Gloucester validation cohort; 2·2, 1·1–4·5, in the QUASAR 2 validation 
cohort; 3·1, 1·9–5·0, in the ovarian carcinoma cohort; 2·5, 1·8–3·4, in the uterine sarcoma cohort; 2·3, 1·2–4·6, in 
the prostate carcinoma cohort; and 4·3, 2·8–6·8, in the endometrial carcinoma cohort). After adjusting for 
established prognostic patient characteristics in multivariable analyses, Nucleotyping was prognostic in all cohorts 
except for the prostate carcinoma cohort (HR 1·7, 95% CI 1·1–2·5, in the discovery cohort; 1·9, 1·1–3·2, in the 
Gloucester validation cohort; 2·6, 1·2–5·6, in the QUASAR 2 cohort; 1·8, 1·1–3·0, for ovarian carcinoma; 1·6, 
1·0–2·4, for uterine sarcoma; 1·43, 0·68–2·99, for prostate carcinoma; and 1·9, 1·1–3·1, for endometrial carcinoma). 
Chromatin heterogeneity was a significant predictor of cancer-specific survival in microsatellite unstable (HR 2·9, 
95% CI 1·0–8·4) and microsatellite stable (1·8, 1·2–2·7) stage II colorectal cancer, but microsatellite instability was 
not a significant predictor of outcome in chromatin homogeneous (1·3, 0·7–2·4) or chromatin heterogeneous 
(0·8, 0·3–2·0) stage II colorectal cancer.
Interpretation The consistent prognostic prediction of Nucleotyping in different biological and technical circumstances 
suggests that the marker of chromatin heterogeneity can be reliably assessed in routine clinical practice and could be 
used to objectively assist decision making in a range of clinical settings. An immediate application would be to 
identify high-risk patients with stage II colorectal cancer who might have greater absolute benefit from adjuvant 
chemotherapy. Clinical trials are warranted to evaluate the survival benefit and cost-effectiveness of using Nucleotyping 
to guide treatment decisions in multiple clinical settings.
Funding The Research Council of Norway, the South-Eastern Norway Regional Health Authority, the National Institute 
for Health Research, and the Wellcome Trust.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY-NC-ND 
4.0 license.
Introduction
Genetic alterations in tumours occur on many different 
levels, ranging from single nucleotide changes and gene 
amplifications, to chromosome translocations and loss 
or gain of whole chromosomes.1 Abnormal chromosome 
number is associated with poor prognosis in many 
common cancer types.2 Higher-order chromatin 
structure regulates gene expression and changes 
during cell differentiation,3 suggesting that chromatin 
reorganisation might contribute to disease pathogenesis. 
Chromatin organisation is also the main determinant of 
variation in regional (ie, on a megabase scale) mutation 
frequency in cancer cells.4,5 Integrating chromatin 
analysis and DNA density measurements could provide 
an objective assessment of genetic instability and 
epigenetic aberrations.
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DNA organisation can be described by the texture of cell 
nuclei stained specifically for DNA, and abnormal 
structure has been linked to poor prognosis in cancer.6 
In previous assessments of chromatin aberrations, 
machine learning algorithms were trained on part of a 
patient cohort with one specific cancer type and validated 
on the complementary part of the same cohort. The 
analysed tissue samples were usually prepared and imaged 
using the same methods and equipment, and attempts to 
make the assessments of chromatin aberrations robust to 
moderate technical deviations have rarely been made, 
which severely limits their applicability, not only in the 
clinic, but also in research facilities. Despite obvious 
limitations, findings from previous studies of this type (eg, 
our own studies on ovarian carcinoma,7 uterine sarcoma,8 
prostate carcinoma,9 and endometrial carcinoma10) suggest 
that such alterations in chromatin organisation could be a 
consistent finding in carcinogenesis. We hypothesised that 
generic texture patterns of aberrant chromatin could be 
detectable in most cancer types and wanted to reliably 
detect these patterns independently of moderate deviations 
in preparation methods and imaging equipment. To this 
end, we developed an automated method to robustly 
identify such patterns and independently validated this 
marker, termed Nucleotyping, in a range of cancer types.
Methods
Patient cohorts
Between 1993 and 2003, 494 consecutive patients with 
primary colorectal cancer at Aker University Hospital 
(Oslo, Norway) had resection of non-synchronous 
stage I and II tumours.11,12 390 of these patients were 
included in our discovery cohort (figure 1A; table 1). 
Two (<1%) patients received adjuvant chemotherapy, and 
324 (83%) patients did not; the information was missing 
for the remaining 64 (16%) patients. Total mesorectal 
excision was done in all patients with rectal cancer 
(n=118), and ten (8%) rectal cancer patients received 
neoadjuvant treatment. None of the colon cancer patients 
(n=272) received neoadjuvant treatment. The study was 
approved by the Regional Committees for Medical and 
Health Research Ethics (REK) in Norway (number 
1.2005.1629). An experienced pathologist (AS) did the 
pathology analyses.
The Gloucester colorectal cancer validation cohort 
included 442 of the 467 patients with non-synchronous 
stage I or II colorectal cancer from the Gloucester 
Colorectal Cancer Study (UK), who were recruited 
between 1988 and 1996 (figure 1B, table 1).13,14 Data on 
adjuvant radiotherapy and chemotherapy were available 
for 310 (70%) patients, of whom 23 (7%) received adjuvant 
treatment and 287 (93%) did not. Total mesorectal 
excision was done in most patients with rectal cancer 
(n=131), and six (5%) patients with rectal cancer received 
neoadjuvant treatment. None of the patients with colon 
cancer (n=311) received neoadjuvant treatment. This 
study was approved by the Gloucestershire Local 
Research Ethics Committee (number 01/21G) and REK 
in Norway (number 2015/1606), and the pathology 
analyses were done by an expert pathologist (NAS).
Histopathology, University 
College London, London, UK 
(Prof M Novelli PhD)
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Research in context
Evidence before this study
In addition to sporadic and systematic review of relevant 
scientific literature over the past decades, we searched PubMed 
without language or time restrictions for articles published until 
Nov 18, 2017, using the terms “nuclear”, “chromatin”, “texture”, 
and “cancer” (full specification of the search criteria is provided 
in the appendix p 2), and systematically reviewed the titles and 
abstracts of the 701 search results. We also searched the digital 
publications collection at The University of Oslo (Oslo, Norway) 
using the terms “texture analysis” and “microscopy images” to 
locate relevant academic theses submitted to the University of 
Oslo in which different methods for detecting chromatin 
aberrations had been evaluated and compared.
Attempts to correlate changes in chromatin organisation with 
cancer diagnosis and prognosis have been made for many 
decades. Early findings suggested that accurate identification of 
disease and patient outcome could be obtained by applying 
complex image analysis methods on images that depict the 
chromatin organisation in cell nuclei, but there is an absence of 
independent validation in external cohorts.
We have previously shown that image patterns associated with 
aberrant chromatin organisation is associated with poor 
prognosis in many cancers, but none of the developed markers 
are suitable for validation on external cohorts of different 
cancer types.
Added value of this study
We have shown that heterogeneous chromatin organisation 
can be reliably assessed by machine learning algorithms 
without being adapted for various cancer types or distinct 
methods and equipment used to prepare the samples and 
image the nuclei. Validation of the chromatin heterogeneity 
marker, termed Nucleotyping, in external cohorts shows that 
chromatin heterogeneity predicts cancer-specific survival of 
patients with colorectal cancer, ovarian carcinoma, uterine 
sarcoma, and endometrial cancer independently of established 
prognostic markers. In stage II colorectal carcinoma, 
cancer-specific survival was stratified more precisely by 
chromatin heterogeneity than by microsatellite instability.
Implications of all the available evidence
The generic utility of Nucleotyping warrants study of its 
molecular basis and suggests that it could enhance selection of 
patients for adjuvant treatment.
See Online for appendix
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432 eligible
390 analysed
62 excluded
16 died of postoperative
complications
46 unknown cause of death
42 unsuccessful sample preparation
16 no tumour material
26 poor specimen quality
A
494 patients with stage I or II colorectal
cancer from Aker University 
Hospital (Discovery cohort)
467 eligible
442 analysed
25 unsuccessful sample preparation
19 no tumour material
  6 poor specimen quality
B
467 patients with stage I or II colorectal
cancer (Gloucester validation
cohort)
441 eligible
391 analysed
50 unsuccessful sample preparation
36 no tumour material
14 poor specimen quality
C
441 patients with stage II colorectal
cancer (QUASAR 2 validation
cohort)
303 eligible
246 analysed
39 excluded
   2 died of postoperative
complications
37 lost to follow-up
3 excluded
1 preoperative radiotherapy
1 died of postoperative
complications
1 lost to follow-up
197 excluded
29 surgery not performed
9 specimen not received
159 not uterine sarcoma
(reviewed diagnosis)
57 unsuccessful sample preparation 
   3 no tumour material
54 poor specimen quality
D
342 patients with stage I ovarian
carcinoma
951 eligible
791 analysed
95 excluded
95 lost to follow-up
160 unsuccessful sample preparation 
38 no tumour material
122 poor specimen quality
G
1046 patients with endometrial
carcinoma
390 eligible
354 analysed
36 unsuccessful sample preparation
15 no tumour material
21 poor specimen quality
E
587 patients with uterine sarcoma
314 eligible
307 analysed
7 unsuccessful sample preparation
7 no tumour material
F
317 patients with prostate carcinoma
Figure 1: CONSORT diagrams showing the origin of each patient cohort
(A) Colorectal cancer discovery cohort. (B) Gloucester colorectal cancer validation cohort. (C) QUASAR 2 colorectal cancer validation cohort. (D) Ovarian carcinoma cohort. (E) Uterine sarcoma cohort. 
(F) Prostate cancer cohort. (G) Endometrial carcinoma cohort.
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The QUASAR 2 trial (ISRCTN registry number 
ISRCTN45133151) established a biobank that included 
formalin-fixed, paraffin-embedded tumour tissue blocks 
from 441 patients with stage II colorectal cancer.15 Data 
from 391 patients were available for the second colorectal 
cancer validation cohort (figure 1C; table 1). Patients were 
recruited between 2005 and 2010, and all patients 
received adjuvant chemotherapy (capecitabine with or 
without bevacizumab), but none received neoadjuvant 
treatment. Approval for the study was obtained from the 
West Midlands Research Ethics Committee (number 
04/MRE/11/18) and REK in Norway (number 2015/1607). 
The pathology assessments were done by pathologists at 
the participating hospitals in the trial.
246 patients treated for International Federation of 
Gynecology and Obstetrics (FIGO) stage I ovarian 
carcinoma between 1982 and 1989 (surgery at county 
hospitals and evaluation of further treatment at the 
Norwegian Radium Hospital, a tertiary referral 
comprehensive cancer centre in Oslo, Norway) were 
analysed as an ovarian cancer validation cohort (figure 1D; 
appendix p 6).7 All patients provided verbal informed 
consent, and the study was in accordance with Norwegian 
law. The surgical procedure consisted of peritoneal 
washing, hysterectomy, bilateral salpingo-oophorectomy, 
and omentectomy. The number of patients who received 
adjuvant treatments and the types of adjuvant treatments 
are described in the appendix (p 24). The FIGO stage was 
reviewed according to 1988 criteria, although para-aortic 
and pelvic lymphadenectomy was not routinely 
performed. A single pathologist (VMA) masked to patient 
outcome reviewed the histological sections using WHO 
criteria.
We confirmed the diagnosis and obtained adequate 
tumour material from 354 patients with uterine sarcoma 
reported to the Norwegian Cancer Registry between 
1970 and 2000 to make up the uterine sarcoma validation 
cohort (figure 1E; appendix p 7).8,16 All patients in this 
cohort had a hysterectomy, but records on the precise 
surgical procedure and additional treatment are not 
available. An experienced gynaecological pathologist 
(VMA) reviewed the tumours according to the WHO 
recommendations without knowledge of the clinical 
outcome. The study of the total population of uterine 
sarcoma patients in Norway was approved by REK 
(number S-04298).
From 1987 to 2005, 317 consecutive patients underwent 
open retropubic prostatectomy at the Norwegian 
Radium Hospital.9,17 One investigator (HW) was 
responsible for treatment and follow-up. 307 patients 
were included in the prostate cancer validation cohort 
(figure 1F; appendix p 8), and the study was approved by 
REK (number S-07443a). Only one patient received 
adjuvant treatment. An experienced uropathologist (LV) 
reviewed all specimens to obtain a complete set of 
consistent pathological assessments using established 
recommendations.18,19
791 tumour samples from consenting patients with 
endometrial carcinoma who were treated between 
2001 and 2011 in the Molecular Markers in Treatment of 
Endometrial Cancer (MoMaTEC) trial (NCT00598845) 
were included in the endometrial carcinoma validation 
cohort (figure 1G; appendix p 9).10 767 patients had 
hysterectomy, three patients had tumour reduction, and 
21 patients had curettage. The number of patients who 
received adjuvant treatment and the types of adjuvant 
treatments are described in the appendix (p 27). Curettage 
specimens were pre operatively assessed to obtain a 
histological risk classifi cation. REK approved the study 
Discovery 
(n=390)
Gloucester 
validation 
(n=442)
QUASAR 2 
validation 
(n=391)
Follow-up time, 
years
6·9 (3·6–10·0) 3·5 (1·7–5·3) 4·8 (4·0–5·1)
Age at surgery, 
years
73 (64–79) 72 (65–79) 63 (57–70)
≤72 190 (49%) 230 (52%) 333 (85%)
>72 200 (51%) 212 (48%) 58 (15%)
Sex
Female 192 (49%) 204 (46%) 161 (41%)
Male 198 (51%) 238 (54%) 230 (59%)
Stage
I 112 (29%) 83 (19%) 0
II 278 (71%) 359 (81%) 391 (100%)
Histological grade
1 37 (10%) 120 (27%) 15 (4%)
2 315 (82%) 257 (58%) 282 (77%)
3 34 (9%) 65 (15%) 68 (19%)
Pathologic tumour (T) stage
T1 23 (6%) 14 (3%) 0
T2 89 (23%) 68 (15%) 0
T3 261 (67%) 236 (54%) 190 (51%)
T4 17 (4%) 123 (28%) 185 (49%)
Microsatellite stability
Unstable 63 (17%) NA 62 (17%)
Stable 300 (83%) NA 306 (83%)
Location
Rectum 118 (30%) 131 (30%) 44 (12%)
Distal colon 116 (30%) 162 (37%) 142 (38%)
Proximal colon 156 (40%) 149 (34%) 188 (50%)
Surgery type
Elective 354 (91%) 366 (85%) NA
Acute* 36 (9%) 65 (15%) NA
Chromatin heterogeneity
Homogeneous 235 (60%) 308 (70%) 244 (62%)
Heterogeneous 155 (40%) 134 (30%) 147 (38%)
Data are median (IQR) or number (%). NA=data not available. *Acute surgery was 
done because of obstruction or perforation of the bowel at presentation in the 
discovery cohort, and defined as either urgent or emergency surgery in the 
Gloucester validation cohort.
Table 1: Baseline characteristics of patients with colorectal carcinoma in 
the discovery and validation cohorts
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(number 052.01), and the 2009 FIGO staging criteria were 
applied to determine FIGO stage. The pathology analyses 
were done by pathologists at the participating centres in 
the trial.
Sample preparation and imaging
Images of cell nuclei were acquired from curettage 
specimens for patients with endometrial carcinoma and 
from the surgically resected tumours for all other patients. 
One of several pathologists selected a representative 
tumour region for each patient from haematoxylin and 
eosin-stained sections of the formalin-fixed, paraffin-
embedded tumour tissue blocks. To account for 
heterogeneity,20 three regions (IQR three to four) from 
different tumour blocks were included for prostate 
carcinoma patients. One or more 50 µm sections of each 
selected tumour region was used to obtain isolated nuclei 
using a modification of Hedley’s method.21 After re-
hydration, the sections were enzymatically digested at 
room temperature at 200 rotations per min (rpm) for 
70 min (for colorectal and prostate specimens) or 60 min 
(for other specimens) with 0·5 mg/mL protease (Sigma 
protease type XXIV [P5380] or type VIII [P8038]; Sigma 
Chemical, St Louis, MO, USA) to disaggregate the cells. 
The cell suspension was filtered through a 60 μm mesh 
nylon filter, washed, and cytospun (600 rpm for 5 min) 
onto a poly-l-lysine-coated slide.22 The nuclei were stained 
using Feulgen’s method, and slides were incubated in 
5 M HCl for 60 min at room temperature for hydrolysis, 
stained with Schiff’s solution for 2 h in the dark, rinsed in 
a fresh solution of 0·5% sodium metabisulfite in 0·05 M 
hydrochloric acid (three times 10 min), dehydrated, and 
coverslipped.21,22 Feulgen-stained nuclei were imaged by a 
Zeiss Axioplan microscope equipped with a 546 nm green 
filter and a monochrome high-resolution digital camera 
(AxioCam MrM, Zeiss, Jena, Germany, or C4742-95, 
Hamamatsu Photonics, Hamamatsu, Japan) with a depth 
of field of about 1·5 µm. In the resulting images, the 
value of each pixel reflects the DNA density at that 
location and is referred to as the pixel grey level. Although 
the sample preparation method and imaging equipment 
were similar within each cohort except for the prostate 
carcinoma cohort, methodological and equipment 
updates were implemented between work on different 
sample series, and images from the entire set of cohorts 
thus have notably different technical features (eg, in 
image contrast and number of nuclear pixels). 
Additionally, a single pathologist selected the tumour 
regions for all patients in the three colorectal carcinoma 
cohorts, the ovarian car cinoma cohort, and the uterine 
sarcoma cohort (although the pathologist was not the 
same across these cohorts), whereas the selections were 
done by multiple pathologists in each of two other 
cohorts.
The imaged nuclei were assessed to exclude non-
representative cells (eg, cut or connected nuclei and 
non-tumour cells). Trained personnel identified the 
nuclei of interest in the ovarian carcinoma cohort as 
those that appeared to be whole, isolated, and epithelial.7 
In all other cohorts, the Ploidy Work Station (PWS, 
Room4, Sussex, UK) was applied to automatically discard 
non-intact nuclei (eg, cut, folded, and connected) and to 
detect cell types. The initial method23 was used in the 
uterine sarcoma cohort, and only non-necrotic, intact 
nuclei were kept for further analysis.8 The analysis was 
further restricted to epithelial nuclei in the colorectal, 
prostate, and endometrial carcinoma cohorts. Trained 
personnel verified the automatic nucleus classifications 
in all cohorts, except in the two colorectal cancer 
validation cohorts because by then we considered the 
method in PWS to be both robust and accurate enough 
to allow completely automated identification of non-
necrotic, intact epithelial nuclei. If less than 200 nuclei 
were classified as applicable for further analysis then the 
specimen was considered of insufficient quality for 
analysis and excluded. 4·3 million images of cell nuclei 
from the 2921 analysed patients were included in further 
analysis, giving an average of about 1200 images per 
tumour region and about 1500 images per patient. Each 
image comprised an average of about 3700 nuclear 
pixels. Because images in different cohorts deviated in 
contrast and size due to differences in sample 
preparation methods and imaging equipment, the set of 
images from each single tumour region was 
independently normalised using a previously described 
algorithm that automatically standardises the optical 
and spatial scales of the images.9 This normalisation 
method does not depend on external controls and 
automatically finds internal controls by estimating 
which nuclei are diploid. The resulting images had a 
physical resolution of about 160 nm/pixel and a pixel 
depth of ten bits.
Nuclear texture analysis
Chromatin organisation was quantified by computing 
the entropy of pixel grey levels in a subregion of a nucleus 
(figure 2). Entropy is a measure of disorder commonly 
used in thermodynamics but applied here to assess 
whether the chromatin organisation is disordered in the 
sense of more interleaved chromatin compartments with 
different condensations. The subregion was taken to be a 
square region, and the entropy of the region was coupled 
with the grey level value of the region’s centre pixel to 
integrate measurements of disordered chromatin 
organisation and DNA content. The frequency in which 
each pair of entropy and centre grey level occur 
throughout a nucleus was stored in a two-way table, 
known as the grey level entropy matrix (GLEM; 
figure 2A).24 Each chromatin pattern (ie, a subregion with 
concrete values and arrangement of pixel grey levels) 
corresponded to a specific element in the GLEM.
GLEMs stratified on nuclear area (grouped at 
1–999 pixels, 1000–1999 pixels, …, 9000–9999 pixels, and 
10 000 pixels or more) and computed on different scales 
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(subregions of 3 × 3 pixels, 5 × 5 pixels, …, 31 × 31 pixels) 
were concatenated to form a four-dimensional expansion 
of the GLEM called GLEM4D.7 Each pixel in a nucleus is 
thus the centre of 15 subregions representing the 
chromatin organisation near the pixel on different 
magnifications, and the frequency of these chromatin 
patterns for all pixels in the nucleus is stored in the 
GLEM4D. The GLEM4D was calculated for each of the 
461 000 nuclear images in the discovery cohort, and each 
patient was represented by the average GLEM4D of the 
patient’s nuclei. Aberrant chromatin patterns were 
discovered as patterns corresponding to elements in the 
GLEM4D that were associated with poor prognosis in the 
discovery cohort. This association was computed for each 
GLEM4D element as a constant scaling factor multiplied 
by the statistic of a two-sample t test that tested for the 
difference between good and poor prognosis in the specific 
GLEM4D element in the discovery cohort. The applied 
adaptive machine learning algorithm25 could then compute 
the compliance between the GLEM4D representation of a 
new patient and the discovered patterns of chromatin 
aberrations by multiplying each GLEM4D element with 
the corresponding scaled t statistic and summing the 
products. The result is a continuous value termed the 
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Figure 2: Computation of the grey level entropy matrix (GLEM) and visualisation of nuclear images
(A) Illustration of GLEM computation. (1) A nuclear image. (2) Each nuclear pixel is taken to be the centre of a square subregion, here with a side length of nine pixels. 
(3) For each subregion, two quantities are extracted (the grey level of the centre pixel [here 22] and the entropy of the grey levels in the subregion [here 3·2]); 
the entropy H is a variability characteristic of the probability mass function P(i) (ie, the histogram that gives the probability P that grey level i occurs in the subregion). 
(4) The two quantities extracted from the subregion will together identify a position in a two-way table. The table cell position corresponding to the subregion in 
figure part 3 of panel A is marked by a green circle in part 4 of panel A. The occurrence is counted by incrementing the value at the table cell position (initially, all table 
cell values are 0), and the computation of the two quantities and incrementation of the corresponding table cell value is performed for every subregion of the nuclear 
image. The resulting table describes the frequency of each pair of centre grey level and surrounding entropy and is normalised by its total count to provide the 
bivariate probability mass function called the GLEM. The two-way table visualised in part A4 is the GLEM of the nuclear image in part A1. (B) Depiction of five nuclear 
images and their chromatin value. The threshold applied to dichotomise the chromatin value was 0·044.
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chromatin value, which describes the overall amount of 
chromatin disorder in a given patient. Finally, the robust 
minimum Euclidean distance classification method26,27 was 
applied to calculate a fixed threshold with which to 
dichotomise the chromatin value into a classification of the 
tumour as either chromatin homogeneous or chromatin 
hetero geneous. The threshold was computed using the 
discovery cohort (0·044), but other thresholds provided 
markers with similar accuracy in the discovery cohort 
when measured by hazard ratio, although with different 
abilities to correctly identify patients as good and poor 
prognosis (appendix p 23). Complete specification of the 
method is provided in the appendix (pp 3–4). Details of 
Nucleotyping and its testing and validation in clinical 
cohorts can be found in a webvideo. Example nuclear 
images and their chromatin values are shown in figure 2B. 
Nucleotyping could subsequently be applied blindly to 
label new, individual patients as chromatin homogeneous 
or chromatin heterogeneous on the basis of the GLEM4Ds 
computed from its nuclear images.
In an average chromatin heterogeneous tumour, 
63% (IQR 52–73) of the nuclei expressed aberrant 
chromatin patterns. The proportion of nuclei required 
for a tumour to be labelled as chromatin heterogeneous 
was not fixed because the classification of a tumour 
sample was based on the average estimated severity of its 
nuclei (the scaled t statistic of the chromatin patterns in 
the nucleus), which in turn was calculated as the average 
severity of all observed chromatin patterns in the nuclear 
image. Thus, a relatively small proportion of nuclei 
(minimum in the analysed cohorts was 36%) expressing 
highly severe chromatin patterns could define the 
tumour as chromatin heterogeneous, whereas a 
chromatin homogeneous tumour could have a relatively 
large proportion of nuclei (maximum in the analysed 
cohorts was 57%) with chromatin patterns associated 
with mild disorganisation.
Statistical analysis
We measured cancer-specific survival because it was 
considered the most clinically relevant endpoint that was 
common to all patient cohorts. Events are defined, as 
proposed by Punt and colleagues,28 exclusively as death 
from the same cancer. All recurrences are ignored, and 
patients are censored at all other deaths or loss to follow-
up. The follow-up time is computed from the date of 
entry to date of death or loss to follow-up. Mantel-Cox log-
rank test was used in univariable survival analysis, and 
Wald χ² test with Cox proportional hazards model in 
multivariable analysis. Each analysis included only 
patients with complete data for the variables in question, 
but imputation for missing data was subsequently done 
using multiple imputation by chained equations to assess 
all patients. The clinical and pathological markers 
included in multivariable analyses were the same as those 
that had been used in the previous studies of the 
individual patient cohorts7–10,12 or, in case of the colorectal 
cancer validation cohorts, were the same prognostic 
markers as those applied to the discovery cohort. 
Subsequently, number of investigated lymph nodes 
(<12 vs ≥12) and tumour sidedness (left vs right) were 
separately added to the multivariable model.
We did sensitivity analyses by repeating analyses without 
patients who had received neoadjuvant or adjuvant 
treatment, or both. Associations were evaluated with 
Spearman’s correlation coefficients.
A likelihood ratio test was used to assess whether 
inclusion of chromatin heterogeneity improved the 
prediction of cancer-specific survival compared with a 
multivariable model without chromatin heterogeneity. The 
proportion of patients with chromatin heterogeneous 
tumours who died of their cancer (positive predictive 
value), the proportion of patients with chromatin 
homogeneous tumours who did not die of their cancer 
(negative predictive value), and the proportion of patients 
who were either both chromatin heterogeneous and died 
of their cancer or chromatin homogeneous and did not die 
of their cancer (correct classification rate) were computed 
to quantify how well chromatin heterogeneity 
corresponded with the final patient outcome.
Category-free net reclassification improvement can be 
defined as the sum of the event-net reclassification 
improvement and non-event-net reclassification 
improvement.29 Event-net reclassification improvement is 
the probability of the new model to estimate worse cancer-
specific survival than the old model in the case of an event, 
minus the probability of the new model to estimate better 
cancer-specific survival than the old model in the case of 
an event. Non-event-net reclassification improvement is 
the probability of the new model to estimate better cancer-
specific survival than the old model in the case of no event, 
minus the probability of the new model to estimate worse 
cancer-specific survival than the old model in the case of 
no event. We used category-free net reclassification 
improvement to evaluate the reclassification from using 
only microsatellite stability status to using both 
Nucleotyping and microsatellite stability status to predict 
the outcome for patients with stage II colorectal cancer.
A two-sided p value of less than 0·05 was considered 
statistically significant. We used MATLAB R2012b for the 
texture analysis and Stata/SE 14.2 for the survival 
analyses. Category-free net reclassification improvement 
was computed using the survIDINRI package 
(version 1.1-1) in R (version 3.4.2).
Role of the funding source
The funders had no role in the study design, data 
collection, data analysis, data interpretation, or in the 
writing of the report. AN had access to the raw data for 
the discovery cohort, NAS for the Gloucester validation 
cohort, DJK for the QUASAR 2 validation cohort, GBK 
for the ovarian carcinoma and uterine sarcoma cohorts, 
HW for the prostate carcinoma cohort, and JT for the 
endometrial carcinoma cohort. The corresponding 
See Online for video
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Figure 3: Kaplan-Meier 
analysis of cancer-specific 
survival in patients with 
chromatin homogeneous 
and chromatin 
heterogeneous tumours  
(A) Discovery cohort for 
colorectal cancer.  
(B) Gloucester validation 
cohort for colorectal cancer. 
(C) QUASAR 2 validation 
cohort for colorectal cancer. 
(D) Ovarian carcinoma cohort. 
(E) Uterine sarcoma cohort. 
(F) Prostate carcinoma cohort. 
(G) Endometrial carcinoma 
cohort. HR=hazard ratio. 
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author had full access to all of the data and the final 
responsibility to submit for publication.
Results
In the colorectal cancer discovery cohort (n=390), 
155 (40%) patients had chromatin heterogeneous tumours 
and 235 (60%) had chromatin homogeneous tumours. 
Patients with chromatin heterogeneous tumours had 
shorter cancer-specific survival than patients with 
chromatin homogeneous tumours, both in univariable 
analysis (hazard ratio [HR] 1·7, 95% CI 1·2–2·5) and 
multivariable analysis (1·7, 1·1–2·5; figure 3A; table 2; 
appendix p 10), and when imputing missing data for 
variables in the multivariable model (1·7, 1·2–2·5). 
Adding tumour sidedness (left vs right) to the multivariable 
model did not substantially alter the results (HR 1·6, 
95% CI 1·1–2·4), nor did removing the 11 patients (all 
with chromatin homogeneous tumours) who received 
neoadjuvant or adjuvant treatment, or both (1·7, 1·2–2·6). 
In patients with stage II colorectal cancer, 5-year 
cancer-specific survival was 83% (95% CI 76–88) for 
patients with chromatin homogeneous tumours 
(26 [16%] cancer-specific deaths out of 164 patients) and 
72% (62–79) for patients with chromatin heterogeneous 
tumours (30 [26%] cancer-specific deaths out of 
114 patients).
Of 442 patients in the Gloucester colorectal cancer 
validation cohort, 308 (70%) had chromatin homogeneous 
tumours and 134 (30%) had chromatin heterogeneous 
tumours. Analysis of the Gloucester cohort replicated the 
results from the discovery cohort (figure 3B; table 2; 
appendix p 11), and chromatin heterogeneity was also 
prognostic when imputing missing data (HR 1·9, 95% CI 
1·1–3·3) or including number of investigated lymph nodes 
(<12 vs ≥12; 1·8, 1·0–3·2) or tumour sidedness (1·9, 
1·1–3·2) in the multivariable model. Excluding the 
29 patients who received neoadjuvant or adjuvant 
treatment, or both (23 patients with chromatin 
homo geneous tumours and six with chromatin 
heterogeneous tumours), gave similar estimates in 
univariable analysis (HR 1·9, 95% CI 1·1–3·5) and multi-
variable analysis (2·0, 1·1–3·6). In patients with stage II 
colorectal cancer, 5-year cancer-specific survival was 
85% (95% CI 78–89) for patients with chromatin 
homogeneous tumours (31 [12%] deaths out of 254 patients) 
and 72% (59–81) for patients with chromatin hetero-
geneous tumours (22 [21%] deaths out of 105 patients).
In the QUASAR 2 colorectal cancer validation cohort, 
147 (38%) of 391 patients had chromatin heterogeneous 
tumours and 244 (62%) had chromatin homogeneous 
tumours. Cancer-specific survival was shorter in patients 
with chromatin heterogeneous tumours than in those 
with chromatin homogeneous tumour (HR 2·2, 95% CI 
1·1-4·5 in univariable analysis; 2·6, 1·2-5·6 in 
multivariable analysis; figure 3C; table 2; appendix p 12). 
Chromatin heterogeneity remained prognostic when 
missing data in the multivariable model were imputed 
(HR 2·3, 95% CI 1·1–4·7). The multivariable result was 
not substantially altered by additionally adjusting for the 
number of investigated lymph nodes (HR 2·7, 95% CI 
1·2–5·9) or tumour sidedness (2·8, 1·3–6·3). 5-year 
cancer-specific survival was 94% (95% CI 90–97) for 
patients with chromatin homogeneous tumours 
(13 [5%] deaths out of 244 patients) and 88% (80–92) for 
patients with chromatin heterogeneous tumours 
(16 [11%] deaths out of 147 patients).
In a pooled analysis of all three colorectal cancer 
cohorts, chromatin heterogeneity was independent of 
sex, stage (II vs I), and pathological tumour stage (T4 vs T3 
vs T2 vs T1; appendix p 13). No association was found for 
colon versus rectum (p=0·48), but chromatin 
heterogeneity correlated weakly with tumour sidedness 
(p=0·12, 95% CI 0·07–0·18; p<0·0001) and therefore 
tumour location (p=0·0010; appendix p 13). Similar weak 
correlations were found for age, histological grade, 
microsatellite stability, and surgery type (appendix p 13). 
Univariable analysis Multivariable analysis* Likelihood ratio 
test*
n HR (95% CI) p value n HR (95% CI) p value p value
Colorectal cancer, discovery 390 1·7 (1·2–2·5) 0·0056 386 1·7 (1·1–2·5) 0·0096 0·0096
Colorectal cancer, Gloucester validation 442 1·8 (1·0–3·0) 0·033 431 1·9 (1·1–3·2) 0·026 0·030
Colorectal cancer, QUASAR 2 validation 391 2·2 (1·1–4·5) 0·027 365 2·6 (1·2–5·6) 0·016 0·015
Ovarian carcinoma 246 3·1 (1·9–5·0) <0·0001 246 1·8 (1·1–3·0) 0·022 0·021
Uterine sarcoma 354 2·5 (1·8–3·4) <0·0001 301 1·6 (1·0–2·4) 0·038 0·035
Prostate carcinoma 307 2·3 (1·2–4·6) 0·012 301 1·4 (0·7–3·0) 0·34 0·35
Endometrial carcinoma 791 4·3 (2·8–6·8) <0·0001 776 1·9 (1·1–3·1) 0·013 0·014
HR=hazard ratio. *In each colorectal cancer cohort, chromatin heterogeneity was added to the multivariable model consisting of age, stage, histological grade, and surgery 
type, although stage was not relevant and surgery type data were not available for the QUASAR 2 validation cohort. For the ovarian carcinoma cohort, the model consisted of 
stage and histological grade. For the uterine sarcoma cohort, the model consisted of histological subtype, mitotic index, tumour extent, tumour size, tumour margins, 
cellular atypia, tumour necrosis, hyaline necrosis, and vascular invasion. For the prostate cancer cohort, the model consisted of age, preoperative prostate-specific antigen, 
Gleason grade, surgical margins, extracapsular extension, seminal vesicle invasion, and pathological node stage. For the endometrial carcinoma cohort, the model consisted 
of age and curettage histology classification. Patients without complete data for model variables were omitted from the multivariable analyses.
Table 2: Chromatin heterogeneity in analysis of cancer-specific survival
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In a pooled analysis of stage II colorectal cancer, the HR 
between patients with chromatin heterogeneous and 
chromatin homogeneous tumours was similar across 
subgroups of each patient characteristic (figure 4). 
Chromatin heterogeneity predicted cancer-specific 
survival more accurately than micro satellite stability 
status (stable vs unstable) and provided prognostic 
information for patients with microsatellite unstable and 
microsatellite stable stage II colorectal cancer (figure 5; 
appendix p 14). In a multi variable model with 
microsatellite stability status, cancer-specific survival was 
shorter in patients with stage II colorectal cancer with 
chromatin heterogeneous tumours compared with 
patients with chromatin homogeneous tumours (HR 1·9, 
95% CI 1·3–2·8). The category-free net reclassification 
improvement of supplementing microsatellite stability 
status with Nucleotyping for prediction of 5-year cancer-
specific survival in stage II colorectal cancer patients was 
31·1% (95% CI 2·7–54·5); the event-net reclassification 
improvement was 7·5%, and the non-event-net 
reclassification improvement was 23·6%.
Of 246 patients in the ovarian carcinoma cohort, 
77 (31%) had chromatin heterogeneous tumours and 
169 (71%) had chromatin homogenous tumours. Patients 
with chromatin heterogeneous tumours had shorter 
cancer-specific survival than those with chromatin 
homogeneous tumours (figure 3D). Chromatin 
heterogeneity was consistently prognostic across a range 
of clinicopathological subgroups and was significant in 
multivariable analysis (table 2; appendix pp 15, 24). 5-year 
cancer-specific survival was 88% (95% CI 82–92) for 
patients with chromatin homogeneous tumours (21 
[12%] deaths out of 169 patients) and 68% (56–77) for 
patients with chromatin heterogeneous tumours 
(25 [32%] deaths out of 77 patients).
Of the 354 patients in the uterine sarcoma cohort, 
201 (57%) had chromatin homogeneous tumours and 
153 (43%) had chromatin heterogeneous tumours. 
Chromatin heterogeneity predicted 5-year cancer-specific 
survival in univariable analysis (figure 3E), performed 
consistently across a range of clinicopathological 
subgroups, and was significant in multivariable analyses 
(table 2; appendix pp 16, 25). Chromatin heterogeneity 
remained prognostic in both univariable (HR 2·4, 95% CI 
1·8–3·1) and multivariable (1·4, 1·0–2·0) analysis of 
cancer-specific survival, also when missing data were 
imputed. 5-year cancer-specific survival was 67% (95% CI 
61–74) for patients with chromatin homogeneous tumours 
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Figure 4: Forest plot of chromatin heterogeneity for all stage II colorectal cancer patients in analysis of cancer-specific survival
*Microsatellite stability data were not available for the Gloucester validation cohort. †Surgery type data were not available for the QUASAR 2 validation cohort. 
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(65 [32%] deaths out of 201 patients) and 35% (28–43) for 
patients with chromatin heterogeneous tumours 
(97 [63%] deaths out of 153 patients).
55 (18%) of the 307 patients in the prostate carcinoma 
cohort had chromatin heterogeneous tumours; the other 
252 (82%) patients had chromatin homogeneous 
tumours. In univariable analysis, cancer-specific survival 
was shorter in patients with chromatin heterogeneous 
tumours than in patients with chromatin homogeneous 
tumours, but there was no significant difference in 
multivariable analysis (figure 3F; table 2; appendix 
pp 17, 26) or when performing imputation for missing 
data (HR 1·43, 95% CI 0·71–2·90; p=0·32). 5-year 
cancer-specific survival was 99% (95% CI 96–100) for 
patients with chromatin homogeneous tumours 
(three [1%] deaths out of 252 patients) versus 94% (83–98) 
for patients with chromatin heterogeneous tumours 
(three [5%] deaths out of 55 patients).
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Figure 5: Cancer-specific survival of stage II colorectal cancer patients according to Nucleotyping and microsatellite stability
Kaplan-Meier curves according to (A) Nucleotyping, (B) microsatellite stability, (C) Nucleotyping in microsatellite unstable tumours, (D) microsatellite stability in 
chromatin homogeneous tumours, (E) Nucleotyping in microsatellite stable tumours, and (F) microsatellite stability in chromatin heterogeneous tumours. 
HR=hazard ratio.
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In the endometrial carcinoma cohort, 118 (15%) of 
791 patients had chromatin heterogeneous tumours and 
673 (85%) had chromatin homogeneous tumours. Patients 
with chromatin heterogeneous tumours had shorter 
cancer-specific survival than those with chromatin 
homogeneous tumours (figure 3G). Chromatin 
heterogeneity was prognostic independent of age at 
surgery and curettage histology classification (table 2; 
appendix pp 18, 27), also when imputing missing data 
(HR 1·9, 95% CI 1·2–3·2). 5-year cancer-specific survival 
was 90% (95% CI 86–92) for patients with chromatin 
homogeneous tumours (50 [7%] deaths out of 673 patients) 
and 62% (49–72) for patients with chromatin heterogeneous 
tumours (32 [27%] deaths out of 118 patients). Exclusion of 
the 260 patients who received adjuvant treatment (192 with 
chromatin homogeneous tumours and 68 with chromatin 
heterogeneous tumours) increased the HR in the 
univariable analysis (HR 10·9, 95% CI 4·8–24·8) and 
multivariable analysis (4·6, 1·8–11·3; appendix pp 19, 28).
The negative predictive value exceeded 90% in the 
two colorectal cancer validation cohorts, the prostate 
cancer cohort, and the endometrial carcinoma cohort, 
but the positive predictive value in these cohorts was not 
higher than 27% (appendix p 20). The positive predictive 
value was higher in the two remaining validation cohorts 
(47% in the ovarian carcinoma cohort and 63% in the 
uterine sarcoma cohort), but the negative predictive value 
was 82% and 68%, respectively (appendix p 20). 
Sensitivity, specificity and correct classification rate for 
all cohorts are shown in the appendix (p 20).
Chromatin heterogeneity showed low positive 
correlation with histological grade in the three 
gynaecological cancer cohorts and in the prostate cancer 
cohort, low negative correlation with histological grade in 
the Gloucester validation cohort, and no correlation with 
histological grade in the discovery cohort or the 
QUASAR 2 validation cohort (appendix p 21). The HR of 
the chromatin heterogeneity marker from the 
multivariable analysis with grade (appendix p 21) was 
similar to the HR derived in the full multivariable 
analyses (table 2).
Of the 2858 patients with assessable DNA ploidy, 
1354 (47%) had diploid tumours, of which eight (<1%) had 
chromatin heterogeneous tumours; the remaining 
1346 (>99%) patients had chromatin homogeneous 
tumours. Of the 1504 non-diploid tumours, 683 (45%) were 
chromatin homogeneous, and 821 (55%) were chromatin 
heterogeneous. In the three colorectal cancer cohorts, 
chromatin heterogeneity divided the non-diploid tumours 
into two groups of similar size (354 [45%] of 785 patients 
with chromatin homogeneous tumours and 431 [55%] 
of 785 patients with chromatin heterogeneous tumours) 
and was not associated with tetraploidy versus aneuploidy 
(p=0·36). Correspondingly, chromatin homogeneity was 
detected in 68 (47%) of 144 non-diploid tumours in the 
ovarian carcinoma cohort, 93 (38%) of 244 non-diploid 
tumours in the uterine sarcoma cohort, 73 (57%) of 127 in 
the prostate carcinoma cohort, and 95 (47%) of 204 in the 
endometrial carcinoma cohort. Diploid chromatin 
homogeneous tumours were associated with longer 
cancer-specific survival than were non-diploid chromatin 
homogeneous tumours in all cohorts, whereas patients 
with chromatin heterogeneous tumours consistently had 
the worst survival (appendix p 22).
Discussion
In all six independent validation cohorts, across a range of 
tumour types, and in the discovery cohort, chromatin 
heterogeneity correlated with cancer-specific survival. 
This suggests that chromatin heterogeneity might be a 
novel pan-prognostic factor irrespective of tumour 
histogenesis, and could add value to the traditional TNM 
staging system. Nucleotyping provided independent 
prognostic information beyond most conventional 
markers in multivariable analyses. Our data permitted 
more in-depth analysis of stage II colorectal cancer, for 
which Nucleotyping was found to be weakly associated 
with other patient characteristics and predicted cancer-
specific survival more accurately than microsatellite 
instability. However, much remains to be discovered of 
the biology underpinning chromatin heterogeneity and 
whether these descriptive changes are associated with 
specific drivers and carcinogenic pathways or are reflective 
of a relatively non-specific burden of accumulated DNA 
damage.
Beside the fundamental biological differences between 
the analysed cancer types, the images from the various 
cohorts were acquired using different sample preparation 
methods and imaging equipment, which cause notable 
dissimilarities between the images, particularly when 
using rigid analytical nomograms. It was thus imperative 
for the developed marker to be invariant to technical 
features of the images. The consistent prognostic ability 
of Nucleotyping across all cohorts empirically shows that 
the recently developed normalisation techniques 
successfully handled technical variations. Similarly, the 
pathologist who selected the tumour region and the 
bioengineers who prepared the samples differed between 
cohorts, thus the consistent validation results suggest 
that the marker is independent of individual human 
influence. This altogether indicates that the marker 
could easily be applied in other laboratories and still be 
expected to perform consistently, which is a necessary 
requirement for mainstream clinical application. 
We have begun the process of obtaining ISO certification 
for the Nucleotyping procedure.
Earlier methods for assessing aberrant chromatin 
organisation have been reported for the ovarian 
carcinoma,7 uterine sarcoma,8 prostate carcinoma,9 and 
endometrial carcinoma cohorts.10 The major difference 
from the present study is that in those studies, a different 
marker was developed in each cohort, which allowed 
adaption to the particular cancer type, sample preparation 
methods, and imaging equipment. None of the earlier 
Articles
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developed markers are suitable for validation on external 
cohorts of different cancer types, and they were only 
validated internally in the same patient series used to 
develop the marker. We therefore find it remarkable that 
the generic marker developed in this study offered 
similar prognostic ability in analysis of ovarian and 
endometrial carcinoma and depicted the prognosis of 
uterine sarcoma and prostate carcinoma with only 
slightly less accuracy compared with the pooled analyses 
of the discovery and internal validation cohorts that were 
reported in those studies. It thus appears that the 
technical standardisation applied in the generic marker 
preserves prognostic information and that texture 
patterns identifying chromatin heterogeneity are 
essentially identical in most cancer types.
The proportion of patients with chromatin homo-
geneous and heterogeneous tumours who died of their 
cancer differed between cancer types, suggesting that 
appropriate use of the chromatin heterogeneity marker 
in the clinic might differ between clinical settings. The 
role of chromatin heterogeneity, as well as options for 
treatment and survival benefits, must therefore be 
investigated in conjunction with disease type and 
characteristics.
In stage II colorectal cancer, our finding of a somewhat 
improved survival in the QUASAR 2 cohort compared 
with the other two colorectal cancer cohorts perhaps 
reflects modern advances in chemotherapy and a more 
consistent application of adjuvant chemotherapy. The 
correlation between Nucleotyping and other patient 
characteristics were either weak or absent, and the 
similar prognostic ability in univariable and multivariable 
analysis of each colorectal cancer cohort further indicates 
that the correlations do not substantially affect 
Nucleotyping’s ability to predict cancer-specific survival 
and might therefore be unimportant in practice. This 
could explain why the proportions of patients with 
chromatin homogeneous and heterogeneous tumours 
were similar in all three cohorts despite the fact that the 
QUASAR 2 series represents a different clinical setting 
than the discovery and Gloucester validation cohorts.
The investigators of original QUASAR trial found that 
adjuvant chemotherapy reduces the odds of tumour 
recurrence and death by about 20% in stage II colorectal 
cancer, leading to a 5-year absolute survival advantage of 
about 4% assuming that the 5-year mortality without 
chemotherapy is 20%.30 Microsatellite stability status is 
often used in clinical practice to identify a subgroup of 
patients with stage II colorectal cancer for whom adjuvant 
treatment can be omitted because these patients are at low 
risk of recurrence and would therefore have a small 
(around 2%) absolute benefit of adjuvant treatment.31–33 
Our data suggest that patients with chromatin 
heterogeneous tumours have poor cancer-specific survival 
irrespective of microsatellite stability status, and the slight 
difference in mortality between microsatellite unstable 
and microsatellite stable tumours in patients with 
chromatin homogeneous tumours was not significant. 
Individually, the chromatin homogeneous subgroup and 
the microsatellite unstable subgroup were associated with 
equally good prognosis (5-year cancer-specific survival 
89% for chromatin homogeneous tumours and 88% in 
microsatellite unstable tumours), but the chromatin 
homogeneous subgroup was several times larger 
(about 60% of patients with stage II colorectal cancer had 
chromatin homogeneous tumours vs 10–15% of patients 
who had microsatellite unstable tumours), thus allowing 
substantially more patients to be identified as low risk and 
with a small absolute benefit of adjuvant chemotherapy. 
Moreover, the patients with chromatin heterogeneous 
tumours have lower cancer-specific survival than patients 
with microsatellite stable tumours and could therefore be 
expected to have a greater absolute survival benefit from 
adjuvant treatment, assuming, reasonably, that the 
proportional benefits of chemotherapy remain constant 
over the different prognostic groups.
Our findings suggest that heterogeneous chromatin 
organisation is found in many cancer types and that its 
presence signifies increased risk of death due to cancer. 
Such generic applicability is a rare feature for a tumour 
biomarker that can be measured objectively using 
automated microscope systems. This assay might 
potentially be cost-effective as it could possibly reduce 
adjuvant overtreatment of patients who are at relatively 
low risk of recurrence and death, thus diminishing the 
burden of toxicity on patients treated unnecessarily and 
the direct costs of cancer therapy. Focusing or intensifying 
adjuvant treatment on those most at risk of death due to 
cancer is consistent with the wider precision medicine 
agenda in oncology.
The main limitation of this study is that it investigates 
the prognostic ability of chromatin heterogeneity but not 
the survival benefit and cost-effectiveness of utilising 
Nucleotyping to guide treatment decisions. However, we 
expect positive findings in this respect because of the 
preserved or enhanced accuracy of Nucleotyping in 
sensitivity analyses where patients who received adjuvant 
therapy were excluded, and our experience with the sample 
preparation method relative to the costs of assessing other 
markers. We also see a potential to improve the cost-benefit 
ratio by assessing chromatin heterogeneity using routine 
histological sections with a DNA-specific stain. Another 
limitation is that tumour heterogeneity was not considered 
except in prostate cancer where it was partly handled by 
analysing about three regions from each tumour; sampling 
the entire tumour should increase the prognostic accuracy 
of the marker.
In conclusion, our results indicate that chromatin 
heterogeneity behaves similarly in several human 
cancers and identifies patients at increased risk of 
cancer-specific death, independently of established 
prognostic markers, and could possibly aid clinical 
decision making around use of adjuvant or neoadjuvant 
therapy.
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